Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: In vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells

International Journal of Pharmaceutics

Volumn 400, Issue 1-2, 2010, Pages 251-259

  Siddiqui, Akhtar ^a   Patwardhan, Gauri Anand ^a   Liu, Yong Yu ^a   Nazzal, Sami ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Antisense oligonucleotide; Cancer therapy; Drug delivery; Solid lipid nanoparticle; Stability

Indexed keywords

ANTISENSE GLUCOSYLCERAMIDE SYNTHASE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; CERAMIDE; CETRIMIDE; DEOXYRIBONUCLEASE I; DOXORUBICIN; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTERNALIZATION; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; OVARY CANCER; PARTICLE SIZE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUCOSYLTRANSFERASES; HUMANS; LIPIDS; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; PARTICLE SIZE;

EID: 77957660685     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.08.044     Document Type: Article

References (33)

1. Asasutjarit R., Lorenzen S., Sirivichayakul S., Ruxrungtham K., Ruktanonchai U., Ritthidej G.C. Effect of solid lipid nanoparticles formulation composition on their size, zeta-potential and potential for in vitro pHIS-HIV-Hugag transfection. Pharm. Res. 2007, 24:1098-1107.
2. Bijsterbosch M.K., Manoharan M., Dorland R., Veghel R.V., Biessen E.A.L., Berkel T.J.C.V. Bis-cholesteryl-conjugated phosphorothioate oligodeoxy-nucleotides are highly selectively taken up by the liver. J. Pharmacol. Exp. Therapeut. 2002, 302:619-626.
3. Bleicher R.J., Cabot M.C. Glucosylceramide synthase and apoptosis. Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids 2002, 1585:172-178.
4. Bondi L.M., Azzolina A., Craparo E.F., Lampiasi N., Capuano G., Giammona G., Cervello M. Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery. J. Drug Target. 2007, 15:295-301.
5. Cabot M.C., Giuliano A.E., Han T.Y., Liu Y.Y. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistance cancer cells. Cancer Res. 1999, 59:880-885.
6. Cui Z.R., Mumper R.J. Genetic immunization using nanoparticles engineered from microemulsion precursors. Pharm. Res. 2002, 19:939-946.
7. Cui Z.R., Mumper R.J. Topical immunization using nanoengineered genetic vaccines. J. Control. Release 2002, 81:173-184.
8. Freitas C., Müller R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm. 1999, 47:125-132.
9. Grünweller A., Gillen C., Erdmann V.A., Kurreck J. Cellular uptake and localization of a Cy3-labeled siRNA specific for the serine/threonine kinase Pim-1. Oligonucleotides 2004, 13:345-352.
10. Gouaze V., Liu Y.Y., Prickett C.S., Yu J.Y., Giuliano A.E., Cabot M.C. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res. 2005, 65:3861-3867.
11. Gouaze V., Yu J.Y., Bleicher R.J., Han T.Y., Liu Y.Y., Wang H., Gottesman M.M., Bitterman A., Giuliano A.E., Cabot M.C. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol. Cancer Ther. 2004, 3:633-639.
12. Gouaze-Andersson V., Cabot M.C. Glycosphingolipids and drug resistance. Biochim. Biophys. Acta 2006, 1758:2096-2103.
13. Hatziantoniou S., Deli G., Nikas Y., Demetzos C., Papaioannou G. Scanning electron microscopy study on nanoemulsion and solid lipid nanoparticles containing high amounts of ceramides. Micron 2007, 38:819-823.
14. Leonetti C., Biroccio A., Benassi B., Stringaro A., Stoppacciaro A., Semple S.C., Zupi G. Encapsulation of c-myc antisense oligonucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther. 2001, 8:459-468.
15. Liu Y.Y., Yu J.Y., Yin D., Patwardhan G.A., Gupta V., Hirabayashi Y., Holleran W.M., Giuliano A.E., Jazwinski S.M., Gouaze-Andersson V., Consoli D.P., Cabot M.C. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J. 2008, 22:2541-2551.
16. Liu Y.Y., Han T.Y., Giuliano A.E., Cabot M.C. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J. Biol. Chem. 1999, 274:1140-1146.
17. Liu Y.Y., Han T.Y., Giuliano A.E., Cabot M.C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001, 15:719-730.
18. Liu Y.Y., Han T.Y., Giuliano A.E., Hansen N., Cabot M.C. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J. Biol. Chem. 2000, 275:7138-7143.
19. Liu Y.Y., Han T.Y., Yu J.Y., Bitterman A., Le A., Giuliano A.E., Cabot M.C. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J. Lipid Res. 2004, 45:933-940.
20. Lucci A., Han T.Y., Giuliano A.E., Cabot M.C. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer 1999, 86:300-311.
21. Lutz O., Meraihi Z., Mura J.L., Frey A., Riess G.H., Bach A.E. Fat emulsion particle size: influence on the clearance rate and the tissue lipolytic activity. Am. J. Clin. Nutr. 1989, 50:1370-1381.
22. Montana G., Bondi B.L., Carotta R., Picone P., Craparo E.F., San Biagio P.L., Giammona G., Carlo M.D. Employment of cationic solid-lipid nanoparticles as RNA carriers. Bioconjug. Chem. 2007, 18:302-308.
23. Norris-Cervetto E., Butters T.D., Dwek R.A., Callaghan R., Platt F.M. Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells. J. Biochem. 2004, 279:40412-40418.
24. Olbrich C., Bakowsky U., Lehr C.-M., Müller R.H., Kneuer C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J. Control. Release 2001, 77:345-355.
25. Patwardhan G.A., Zhang Q.J., Yin D., Gupta V., Bao J., Senkal C.E., Ogretman B., Cabot M.C., Shah G.V., Sylvester P.W., Jazwinski S.M., Liu Y.Y. A new mixed backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis. PLosONE 2009, 4:1-11.
26. Pozo-Rodrίguez A.D., Delgado D., Solinί M.A., Gascón A.R., Pedraz J.L. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int. J. Pharm. 2007, 339:261-268.
27. Stover T.C., Sharma A., Robertson G.P., Kester K. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin. Cancer Res. 2005, 11:3465-3474.
28. Tabatt K., Kneuer K., Sameti M., Olbrich C., Müller R.H., Lehr C.M., Bakowsky U. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J. Control. Release 2004, 97:321-332.
29. Tabatt K., Sameti M., Olbrich C., Müller R.H., Lehr C. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticles-mediated gene transfer. Eur. J. Pharm. Biopharm. 2004, 57:155-162.
30. Vighi E., Ruozi B., Montanari M., Battini R., Leo E. Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid. Eur. J. Pharm. Biopharm. 2007, 67:320-328.
31. Vogel V., Lockmann D., Weyermann J., Mayer G., Broek van den J.A., Hasse W., Wouters D., Schubert U.S., Kreuter J., Zimmer A., SChubert D. Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties, and intracellular distribution. J. Control. Release 2005, 103:99-111.
32. Weyermann J., Lochmann D., Zimmer A. Comparison of antisense oligonucleotide drug delivery systems. J. Control. Release 2004, 100:411-423.
33. Yessine M., Meier C., Petereit H., Lerous J. On the role of methacrylic acid copolymers in the intracellular delivery of antisense oligonucleotides. Eur. J. Pharm. Biopharm. 2006, 63:1-10.